David J. Vigerust, MS., PhD Named Chief Scientific Officer of Spectrum Solutions

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

April 14, 2021

David J. Vigerust, MS, Ph.D. has founded, led as CEO, and previously served as chief scientific officer for a number of progressive life science and advanced biotech companies.

Much of Dr. Vigerust’s success is attributed to his superior logical and analytical approach in formulating innovative, non-linear industry solutions.

“Not only is Dr. Vigerust an award-winning and highly respected researcher and professor, he also has a deep foundational and highly practical scientific knowledge across multiple disciplines in biotechnology, medicine, and life science,” said Stephen Fanning, CEO of Spectrum Solutions.

In addition to his new role at Spectrum, Dr. Vigerust additionally holds teaching positions at Vanderbilt University Medical Center in the Department of Neurological Surgery as well as the University of Maryland, Eastern Shore School of Pharmacy. Throughout his career, he has developed several novel molecular diagnostic assays for the prediction of cardiovascular risk in patients with diabetes, infectious disease and cancer.

Over the past 20 years he has been the recipient of many research awards and honors including his selection as the 2016 TEDx presenting industry expert and speaker on the subject of precision medicine.

Dr. Vigerust received a bachelor’s degree in biology and chemistry from the University of Texas at El Paso, a master’s degree in microbiology and immunology from Texas Tech University in Lubbock, and a Ph.D. in cellular and molecular pathology from Vanderbilt University in Nashville, TN. Dr. Vigerust conducted post-doctoral research on viral glycosylation, host defense from influenza, and bacterial secondary infection in the Department of Infectious Disease at St. Jude Children’s Research Hospital. He completed a second post-doctoral fellowship at Vanderbilt University Medical School in the Department of Pediatric Infectious Disease in the area of molecular biology of respiratory viruses.

Dr. Vigerust has presented his research at national and international conferences and he is also an active editor and reviewer for several medical journals. He has been published in 26 peer-reviewed journals including Enhancement of Innate Immunity to COVID-19 with Natural Measures, published in Immunome Research in October 2020 and Microvascular disease confers additional risk to COVID-19 infection published in Medical Hypothesis in November, 2020.



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.